Double-Punch immune therapy tested for Tough-to-Treat leukemia
NCT ID NCT06735690
Summary
This early study is testing a two-part immune therapy for adults with high-risk acute lymphoblastic leukemia (ALL) who have just received a stem cell transplant from a matched relative. The goal is to see if giving specially engineered immune cells (CAR T-cells) followed by a vaccine is safe and can help prevent the cancer from coming back. The study will enroll about 15 people to first check for safety and see if the treatment approach is feasible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.